## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL 287

	OMB Number: Estimated average burd hours per response:	3235-0287
	Estimated average burd	en
ı	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Schacterle Amy  (Last) (First) (Middle)  C/O ACUMEN PHARMACEUTICALS, INC.  1210-1220 WASHINGTON STREET, SUITE 210						2. Issuer Name and Ticker or Trading Symbol Acumen Pharmaceuticals, Inc. [ ABOS ]  3. Date of Earliest Transaction (Month/Day/Year) 01/06/2025									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify below) below)  Chief Regulatory Officer						
																					(Street) NEWTON MA 02465 (City) (State) (Zip)
1. Title of S	Security (Inst		ne i - Noi	2. Trans		1	2A. Deem	ed	3.		4. Securi	ties Acqui	red (A)	or	5. Amou	nt of	6. Own		. Nature		
Date (Month/I					Day/Ye	ear)	if any	xecution Date, any Month/Day/Year)		Code (Instr.   5)		d Of (D) (In	str. 3, 4	Benefici Owned I		ially (D) Following (I) (I		or Indirect   E	of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	nt (A) or P		rice Reporte Transac (Instr. 3		ion(s)					
Common Stock 01/06/							/2025				8,800	,800 <sup>(1)</sup> A		\$ <mark>0</mark>	8,800		I	D			
		-	Fable II - I								osed of, onvertil				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	d Date,	4. Transaction Code (Instr 8)		5. Number of		6. Date E. Expiratio (Month/D	cercis	able and			unt 8	B. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownershi (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amor or Num of Share	ber							
Employee Stock Option (right to buy)	\$1.85	01/06/2025			Α		13,200		(2)		01/06/2035	Common Stock	13,2	200	\$0	13,200		D			

## Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.

## Remarks:

/s/ Derek Meisner, Attorney-in-

Fact

\*\* Signature of Reporting Person Date

01/07/2025

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.